Vertanical’s Exilby Wins First European Approval for Chronic Pain
GRÄFELFING, Germany – June 9, 2026 VERTANICAL has achieved a major milestone in chronic pain treatment after receiving Germany’s...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
GRÄFELFING, Germany – June 9, 2026 VERTANICAL has achieved a major milestone in chronic pain treatment after receiving Germany’s...
HERZLIYA, Israel and CALGARY, Alberta, May 27, 2026 Innocan Pharma Corporation has reported strong first-quarter 2026 financial results, highlighting...
GLEN ALLEN, Va., April 22, 2026 Adial Pharmaceuticals, Inc. announced the successful completion of demonstration batch production for its...
